Drawing for Serial No. 79307816

USPTO serial 79307816

Serial No. 79307816

Reviewed by CopyMark Law Group

Reg. 6749208Status 700Registered
Filing date
Status date
Registration date
Jun 7, 2022
Examiner
BETTS, MARCYA
Law office
TMEG LAW OFFICE 106

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79307816?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kenya Williams

Kenya Williams Thermo Fisher Scientific5781 Van Allen WayCarlsbad, CA 92008United States

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic kits consisting primarily of antibodies, buffers and reagents for use in measuring proteins, antibodies, antigens and other substances in the blood, other bodily fluids and body tissues for the diagnosis of disease and other conditions in humans and animals in the fields of cancer, immunology and haemotology; immunological test kits consisting primarily of diagnostic preparations for use in measuring proteins, antibodies, antigens and other substances in the blood, other bodily fluids and body tissues for the diagnosis of disease and other conditions in humans and animals in the fields of cancer, immunology and haemotology; reagents for use in medical diagnosis; diagnostic and biological reagents for medical use; medical diagnostic assays, namely antibodies, nephelometric assays, turbidimetric assays, chemistry assays and enzyme assays for testing of bodily fluids; calibrating solutions for medical diagnostic assays for testing of bodily fluids; diluents for medical diagnostic assays for testing of bodily fluids; control samples for medical diagnostic assays for testing of bodily fluids; none of the aforesaid products to be used in relation to dialysis and/or fluid therapyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 12, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 12, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 12, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 21, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 30, 2023NURCNOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED—
Apr 24, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 24, 2023COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Apr 21, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 17, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 22, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 22, 2022FIMPFINAL DISPOSITION PROCESSED—
Sep 7, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 1, 2022ES7RTEAS SECTION 7 REQUEST RECEIVED—
Jun 7, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jun 7, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 22, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 22, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 21, 2022GPNXNOTIFICATION PROCESSED BY IB—
Mar 2, 2022OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 2, 2022OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 2, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 14, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 21, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 20, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 20, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 5, 2021RFNTREFUSAL PROCESSED BY IB—
Aug 16, 2021RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 16, 2021RFRRREFUSAL PROCESSED BY MPU—
Aug 3, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 2, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 22, 2021DOCKASSIGNED TO EXAMINER—
Apr 13, 2021MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 7, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 1, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance